Key Information
Program Description
Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is a progressive, life-threatening disease caused by the misfolding of transthyretin proteins into amyloid fibrils that deposit in the heart, leading to restrictive cardiomyopathy and heart failure. Despite its severity, ATTR-CM is frequently underdiagnosed or delayed as symptoms often overlap with more common conditions. This session is designed to equip managed care professionals and pharmacists with the clinical and economic insights necessary to resolve diagnostic and treatment delays in ATTR-CM. Through a review of current therapies, including established TTR stabilizers, as well as the expanding role of TTR gene silencers and other investigational agents, expert speakers will explore critical considerations in treatment sequencing, the interpretation of serum TTR as a biomarker, and the application of health economic data to inform sustainable formulary decisions. By highlighting the pivotal role of the managed care pharmacist in multidisciplinary teams, this program aims to optimize patient-centered access, improve therapy adherence, and leverage emerging diagnostic tools to reduce the systemic and economic burden of ATTR-CM.